U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ONLINE SEARCH REQUEST FORM

USER Shep Rose SERIAL NUMBER 753907

ART UNIT 125 PHONE 308-7602 DATE 3/3/92

Please give a detailed statement of requirements. Describe as specifically as possible the subject matter to be searched. Define any terms that may have special meaning. Give examples or relevant citations, authors, or keywords, if known.

You may include a copy of the broadest and or relevant claim(s).

In each of Cas Online, Derwent, Biosis & Medline and 1989 or earlier only in print full with abstracts please

I a fluticasone or fluticasone propionate
or RN 80474-14-2
or RN 136112-02-02

Id print out all entries on I } L4

Ib with one of: asthma or inhalation or metered dose L5 -3
or inhaler or aerosol

II print out all entries of I
with salmeterol or RN 89365-50-4 } L9 -3

III print out all entries of I with salbutamol a.k.a. RN } L10 -2

IV print out Family of Patents for Derwent for
GT.BR. 2.088877 → CAN 96(19) 163044p
GT.BR 2 140 800 102(11)095383p

V Find abstracts in chemabstracts for IV (& family members) & print out

EQUIVALENS
+CA ref

STAFF USE ONLY

COMPLETED _____
SEARCHER _____
ONLINE TIME _____ (in minutes) TOTAL TIME _____
NO. OF DATABASES _____

SYSTEMS
____ CAS ONLINE
____ DARC/QUESTEL
____ DIALOG
____ SDC
____ OTHER

'102' IS NOT A VALID ACCESSION NUMBER

COMMAND STACK INTERRUPTED. ENTER "DISPLAY HISTORY"
TO SEE WHICH COMMANDS WERE EXECUTED.

=> d acc all 102:095383p

ANSWER 1 COPYRIGHT 1992 ACS
AN CA102(11):95383p
TI Phenethanolamine derivatives useful in the treatment of respiratory problems
AU Skidmore, Ian Frederick; Lunts, Lawrence Henry Charles; Finch, Harry; Naylor, Alan
CS Glaxo Group Ltd.
LO UK
SO Ger. Offen., 82 pp.
PI DE 3414752 A1 18 Oct 1984
AI DE 84-3414752 18 Apr 1984
PRAI GB 83-10477 18 Apr 1983
GB 83-17087 23 Jun 1983
GB 83-29568 4 Nov 1983
GB 84-1889 25 Jan 1984
IC C07C093-08; C07D317-54; C07D319-18; A61K031-135
SC 25-10 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
SX 63
DT P
CO GWXXBX
PY 1984
LA Ger
GI Diagram(s) available in offline prints and/or printed CA Issue.
AB Title compds. (I) (m = 2-8; n = 1-7; Ar = aryl, R, R1 = H, C1-3 alkyl) were prepd. as .beta.-adrenoreceptor stimulants (no data). Thus 4,3-(HO)(HOCH2)C6H3CH(OH)CH2NH2 was alkylated with Br(CH2)6OCH2CH2Ph to give the analog II.
KW araliph amino alc sympathomimetic
IT Sympathomimetics
((aminomethyl)benzyl alc. derivs.)
IT Aminolysis
(of araliph. bromides)
IT Etherification
(of benzenealkanols)
IT 106-31-0 123-62-6 94749-45-8
(Grignard reaction of, with bromopentane deriv.)
IT 108-24-7
(Grignard reactions of)
IT 24085-19-6 94749-47-0
(alkylation of)
IT 27475-14-5 36256-45-8 94749-61-8
(amination of)
IT 94749-00-5
(aminolysis with, of oxirane deriv.)
IT 60-12-8 122-97-4 699-02-5 702-23-8 928-51-8 1875-88-3 3360-41-6 5182-44-5 5406-18-8 7589-27-7 10493-38-6 10521-91-2 22545-13-7 30595-80-3 52244-70-9 76727-24-7
(etherification of)
IT 110-52-1 111-24-0 4549-31-9
(etherification with, of benzenealkanols)
IT 629-03-8
(etherification with, of benzenealkenols)
IT 4549-32-0
(etherification with, of benzeneethanol)
IT 79-31-2
(lithiation-alkylation of)

IT 94749-46-9P
(prepn. and alkylation of)
IT 94749-20-9P 94749-21-0P 94749-22-1P 94749-23-2P 94749-24-3P
94749-25-4P 94749-26-5P 94749-27-6P 94749-28-7P 94749-29-8P
94749-30-1P 94749-31-2P 94749-32-3P 94749-33-4P 94749-34-5P
94749-35-6P 94749-36-7P 94749-37-8P 94749-38-9P 94749-39-0P
94749-70-9P 94749-72-1P 94749-73-2P
(prepn. and amination of)
IT 94749-65-2P
(prepn. and conversion into isocyanate)
IT 94749-69-6P
(prepn. and cyclization of)
IT 94749-48-1P
(prepn. and deprotection of)
IT 2430-16-2P 41302-05-0P 58403-57-9P 94749-41-4P 94749-42-5P
(prepn. and etherification of)
IT 94749-67-4P 94749-71-0P
(prepn. and hydrogenolysis of)
IT 94799-94-7P
(prepn. and methylation of)
IT 94749-63-0P
(prepn. and reaction with Et chloroformate)
IT 94749-66-3P
(prepn. and reaction with benzyl alc.)
IT 94749-64-1P
(prepn. and reaction with sodium azide)
IT 702-15-8P 94749-40-3P 94749-49-2P 94749-50-5P 94749-51-6P
94749-52-7P 94749-53-8P
(prepn. and reactions of)
IT 94749-62-9P
(prepn. and redn. of)
IT 94749-54-9P 94749-55-0P 94749-56-1P 94749-57-2P 94749-58-3P
94749-59-4P
(prepn. and reductive alkylation of)
IT 94749-68-5P
(prepn. and resoln. of)
IT 94748-99-9P 94749-01-6P 94749-43-6P 94749-44-7P 94771-31-0P
94840-92-3P
(prepn. of)
IT 94748-69-3P 94748-70-6P 94748-71-7P 94748-72-8P 94748-73-9P
94748-74-0P 94748-75-1P 94748-76-2P 94748-77-3P 94748-78-4P
94748-79-5P 94748-80-8P 94748-81-9P 94748-82-0P 94748-83-1P
94748-84-2P 94748-85-3P 94748-86-4P 94748-87-5P 94748-88-6P
94748-89-7P 94748-90-0P 94748-91-1P 94748-93-3P 94748-94-4P
94748-95-5P 94748-96-6P 94748-97-7P 94748-98-8P 94749-02-7P
94749-03-8P 94749-04-9P 94749-05-0P 94749-06-1P 94749-07-2P
94749-08-3P 94749-09-4P 94749-10-7P 94749-11-8P 94749-12-9P
94749-13-0P 94749-14-1P 94749-15-2P 94749-16-3P 94749-17-4P
94749-18-5P 94749-19-6P
(prepn. of, as sympathomimetic)
IT 503-30-0
(reaction of, with (bromopropyl)benzene)
IT 637-59-2
(reaction of, with oxetane)
IT 32634-68-7
(resoln. with, of amino ester)

=>
=> d acc 96:163044p all

ANSWER 1 COPYRIGHT 1992 ACS
AN CA96(19):163044p
TI Androstane carbothioates
CS Glaxo Group Ltd.

PI NL 8100707 A 16 Sep 1981
AI NL 81-707 13 Feb 1981
PRAI GB 80-5174 15 Feb 1980
GB 80-13339 23 Apr 1980
IC C07J003-00; A61K031-56
SC 32-4 (Steroids)
DT P
CO NAXXAN
PY 1981
LA Neth
GI Diagram(s) available in offline prints and/or printed CA Issue.
AB Antiinflammatory (no data) androstanes I (R = CH2F, CH2Cl, CH2Br, CH2CH2F; R1 = acyl; R1R2 = CH2O; R2 = H, .alpha.- or .beta.-Me, R7 = H; R2R7 = CH2; R3 = H, Cl, F; R4 = H, F; R5 = R6 = H; R5R6 = bond) were prepd. Thus, I (R = CH2Cl, R1 = COEt, R2 = .beta.-Me, R3 = F, R4 = H, R5R6 = bond, R7 = H) was prepd. by treating the corresponding 17-carboxylic acid with Me2NCSCl, hydrolyzing to the 17-thiocarboxylic acid, and esterifying with BrCH2Cl.
KW halomethyl androstanecarbothioate; antiinflammatory halomethyl androstanecarbothioate
IT Inflammation inhibitors and Antiarthritics
(halomethyl androstanecarbothioates)
IT 28416-82-2 37927-29-0
(acylation of)
IT 53-34-9 338-95-4 2282-51-1
(oxidn. of)
IT 80473-87-6P 80473-92-3P 80474-39-1P 80486-66-4P 80486-69-7P
(prepn. and acylation of)
IT 80473-82-1P 80474-61-9P 80474-66-4P 80474-67-5P 80474-73-3P
80474-74-4P
(prepn. and chlorination of)
IT 80486-68-6P
(prepn. and collagen exchange of)
IT 80473-96-7P
(prepn. and deacylation of)
IT 80473-84-3P
(prepn. and elimination of oxygen from)
IT 80473-85-4P 80473-88-7P 80474-34-6P 80474-38-0P 80474-43-7P
80474-45-9P
(prepn. and esterification of)
IT 80474-11-9P 80483-93-8P
(prepn. and fluorination of)
IT 80474-33-5P 80474-37-9P 80474-50-6P 80474-51-7P 80474-52-8P
80474-53-9P 80474-54-0P 80474-55-1P 80474-56-2P 80474-57-3P
80474-58-4P 80474-59-5P 80474-60-8P
(prepn. and hydrolysis of)
IT 80473-97-8P
(prepn. and oxidn. of)
IT 37927-23-4P
(prepn. and reaction of, with dimethylthiocarbamoyl chloride)
IT 80474-00-6P 80474-19-7P 80474-32-4P
(prepn. and redn. of)
IT 79578-10-2P 80473-90-1P
(prepn. and thiolation of)
IT 65429-42-7P 80473-83-2P 80473-86-5P 80473-89-8P 80473-91-2P
80473-93-4P 80473-94-5P 80473-95-6P 80473-98-9P 80473-99-0P
80474-01-7P 80474-02-8P 80474-03-9P 80474-04-0P 80474-05-1P
80474-06-2P 80474-07-3P 80474-08-4P 80474-09-5P 80474-10-8P
80474-12-0P 80474-13-1P 80474-14-2P 80474-15-3P 80474-16-4P
80474-17-5P 80474-18-6P 80474-20-0P 80474-21-1P 80474-22-2P
80474-23-3P 80474-24-4P 80474-25-5P 80474-26-6P 80474-27-7P
80474-28-8P 80474-29-9P 80474-30-2P 80474-31-3P 80474-35-7P
80474-36-8P 80474-40-4P 80474-41-5P 80474-42-6P 80474-44-8P
80474-46-0P 80474-47-1P 80474-48-2P 80474-49-3P 80474-62-0P

80486-70-0P 80486-71-1P
(prepn. of)
IT 16420-13-6
(reaction of, with androstanecarboxylic acids)
IT 3800-28-0 52510-14-2 65751-34-0
(reaction of, with dimethylthiocarbamoylchloride)
IT 28416-82-2 37926-75-3 37927-06-3 59861-01-7
(thiolation of)

=>
=>
=>
=> log y

```
      06mar92 15:06:49 User021071 Session B2093.1
            $0.11    0.003 Hrs File1
     $0.11  Estimated cost File1
     $0.04  TYMNET
     $0.15  Estimated cost this search
     $0.15  Estimated total session cost   0.003 Hrs.

SYSTEM:OS  - DIALOG OneSearch
  File 350:Derwent World Patents Index
         1963-1980, EQUIVALENTS THRU DW=9151
 **FILE350: KWIC & HILIGHT are available.  Format 9 in a full record format
 New predefined format 29 is equivalent to format 3 plus the basic abstract
  File 351:Derwent World Patents Index Latest
         1981+; DW=9202, UA=9136, UM=9119
 **FILE351: KWIC & HILIGHT are available.  Format 9 in a full record format
 New predefined format 29 is equivalent to format 3 plus the basic abstract

      Set  Items  Description
      ---  -----  -----------
?s pn=gb2088877

      S1       1  PN=GB2088877
?t1/3


 1/7/1     (Item 1 from file: 351)
003207407  WPI Acc No: 81-67960D/38
XRAM Acc No: C81-D67960
   Haloalkyl androstane-17-carbothioate ester(s) useful as topical
   antiinflammatory agents
Patent Assignee: (GLAX ) GLAXO GROUP LTD
Number of Patents: 030
Patent Family:
    CC Number    Kind     Date      Week
    BE 887518      A     810813     8138   (Basic)
    SE 8101010     A     810914     8140
    FR 2477156     A     810904     8141
    NL 8100707     A     810916     8142
    FI 8100444     A     810930     8143
    PT 72502       A     811012     8144
    DK 8100623     A     811012     8145
    JP 56138200     A     811028     8149
    DE 3105307     A     811210     8151
    FR 2485542     A     811231     8206
    GB 2088877     A     820616     8224
    US 4335121     A     820615     8226
    ZA 8100976     A     820519     8234
    ES 8305379     A     830701     8334
    GB 2088877     B     840704     8427
    ES 8402317     A     840416     8423
    CH 644615      A     840815     8438
    GB 2137206     B     850403     8514
    ES 8502447     A     850401     8524
    CH 651307      A     850913     8542
    CA 1201114     A     860225     8613
    US 4578221     A     860325     8615
    ES 8600936     A     860216     8618
    CA 1205464     A     860603     8627
    DE 3153379     A     870226     8709
    US 4650610     A     870317     8713
    SE 452468      B     871130     8750
    JP 88037120     B     880722     8833
```

Priority Data (CC,No,Date): GB 8013339 (800423); GB 805174 (800215); GB 814496 (810213); GB 8325400 (830000);
Applications (CC,No,Date): GB 8325400 (830922); US 513396 (830714); ES 532055 (840430); DE 3153379 (810213); US 753428 (850710); JP 8120790 (810213); DE 3105307 (810213);
Filing Details: GB2137206 Derived from 13.02.81-004496; US4578221 (+23.4.81, 17.8.82-US-256845, 408837) (1665SE); DE3153379 Div.ex.3105107; US4650610 C.i.p 4578221 (+23.4.81, 17.8.82, 14.7.83-US-256845, 408837, 513396) (1665CJ); DE3105307 Add to 3153379 (1822JS)

Abstract (Basic): Carbothioate esters of formula (I) are new. In (I) R1 isCH2F, CH2Cl, CH2Br or CH2CH2F; R2 is 2-4C alkanoyl or OR2 + R3 is 16 alpha, 17 alpha-isopropylidenedioxy; R3 is H, alpha- or beta-Me or =CH2; R4 is H, Cl or F; R5 is H or F. Intermediates of formula (II) and their salts are new. In (II) Ra is COOCSNRARB or COSR1A, where RA and RB are alkyl or NRARB is a 5- to 8-membered ring opt. contg. another heteroatom (O, N or S) and opt. mono- or disubstd. by 1-3C alkyl, and R1A is H, R1 or a gp. convertible to R1; Rb is esterified OH or forms an isopropylidenedioxy gp. with Rc or Rb can be OH when Ra is COSR1A; Rc is H, Me or =CH2; Rd is opt. protected OH or oxo and Re is H, Br, Cl or F, or Re + Rd is a C-C bond or a beta-epoxy gp.; Rf is H or F.

(I) are antiinflammatory agents with a high ratio of topical to systemic activity. (74pp)

Abstract (US): 8713 US 4650610

Androstane and carbothioic acids and salts of formula (I) are new. In (I), R1 is H, OH in alpha configuration, Me in alpha or beta-configuration or methylene; R2 is OH opt. protected (alpha or beta) or oxo; R3 is H, Br, Cl, F or R2 and R3 together are C-C bond or epoxy gp. in beta-configuration; R4 is H or F. Esp. cpds. include 9alpha-fluoro-11beta 17alpha-dihydroxy -16beta-methyl--3-oxoandastra-1,4-diene 17beta-carbothioic acid. (I) may be prepd. e.g. by reacting a reactive deriv. of 17beta-carboxylic acid (II) pref. (III)), with H2S or sulphide or hydrosulphide.

USE - (I) are intermediates to corresp. 17beta-carbothioate esters by esterification and to the 17alphaacyloxy and 16alpha 17alpha-acetonide cpds. which are anti-inflammatories. @(9pp)@ 8615 US 4578221

Androstane hydroxy carbothioic acids and salts of formula (I) are new. In (I), R1 is H, OH in alpha configuration, Me in either alpha or beta or methylene; R2 is opt. protected in either alpha or beta configuration or methylene; R3 is H, Br, Cl, F or R2 and R3 together are C-C bond or epoxy in beta configuration; R4 is H or F and dotted line is single or double bond.

(I) is prepd. by reacting reactive deriv. of corresp. 17-beta-carboxylic acid cpd. (III) with H2S, sulphide or hydrosulphide salt. In (III), R5 is gp(a) with X, Y and Z each CH or N2 one or two being N, the ring opt. substd. lower alkyl or Bz. (III) is pref. prepd. by reaction of reactive deriv. of corresp. 17-beta-carboxylic acid (II) with R5-W-R5 in which W is CO, CS, SO or SO2 (pref. N, N'-carbonyldiimidazole or N-N'-thiocarbonyl-diimidazole). New process for prepn. of cpd. (V) in which Ra is 1-6C alkyl or 1-2C alkyl with terminal halo or Bz opt. substd. 1-4C-alkyl or -alkoxy or halo comprises esterifying (I) or its salt.

USE - (I) are intermediates to anti-inflammatory androstane 17-beta-carbothioate esters. The process allows prepn. of the 17-beta-carbothioate esters when corresp. thiols are not available. @(9pp)@

Abstract (GB): 8514 GB 2137206

Compounds of the general formula (II) (wherein Ra represents a thiocarbamoyloxycarbonyl group -COOCSNRARB (where RA and RB which may be the same or different, are alkyl groups or RA and RB together with the nitrogen atom to which they are attached form a 5-8 membered ring which may optionally contain an additional hetero atom selected from oxygen, nitrogen and sulphur and/or which may be optionally substituted

for R1 or is the group -(CH2)nY in which n is 1 or 2 and Y represents a displaceable substituent) and Rb represents an esterified hydroxyl group or Rb and Rc together represent an isopropylidenedioxy group; or where Ra represents a group COSR(1A), Rb is optionally a hydroxyl group; Rc represents a hydrogen atom, a methyl group (which may be in either the alpha- or beta-configuration) or a methylene group; Rd represents a hydroxy or protected hydroxy group (in either the alpha- or beta-configuration)or an oxo group; Re represents a hydrogen, bromine, chlorine or fluorine atom; or Rd and Re together represent a carbon-carbon bond or an epoxy group in the beta-configuration; Rf represents a hydrogen or a fluorine atom; and salts of those compounds which have a free carbothioic acid group; with the exclusion of compounds of the formula (I) wherein R1 represents a fluoro-, chloro- or bromo- methyl group or a 2'-fluoroethyl group, R2 represents a group COR6 where R6 is a C1-3 alkyl group or OR2 and R3 together form a 16alpha,17alpha isopropylidenedioxy group; R3 represents a hydrogen atom, a methyl group (which may be in either the alpha- or beta-configuration) or a methylene group; R4 represents a hydrogen, chlorine or fluorine atom; R5 represents a hydrogen or fluorine atom. 8427 GB 2088877

Cpds. of the formula (I) wherein R1 represents a fluoro-, chloro- or bromo-methyl gp. or a 2'-fluoroethyl gp., R2 represents a gp. COR6 where R6 is a C1-3 alkyl gp. or OR2 and R3 together form a 16alpha,17alpha isopropylidenedioxy gp.; R3 represents a hydrogen atom, a methyl group (which may be in either the alpha- or beta-configuration) or a methylene gp.; R4 represents a hydrogen, chlorine or fluorine atom; R5 represents a hydrogen or fluorine atom and the dotted line represents a single or double bond.

Abstract (DE): 8839 DE 3105307

Androstan-carbothioate of formula (I) is new, where R1 = F, Cl, Br or 2'-fluoroethyl. R2 = COR6 (R6 = 1-3C alkyl); or OR2 and R3 form 16 alpha, 17 alpha-isopropylidene dioxy together R3 = H, alpha- or beta-methyl or methylene. R4 = H, Cl or F. R5 = H or F and dotted lines (I) within benzyl denote single or double bond.

5 cpds. are specifically claimed including S-Chloromethyl-9alpha -fluoro-11 beta-hydroxy-16 alpha-methyl-3-oxo-17 alpha propionyloxy androsta-1,4-dien-17 beta carbothioate.

6 methods of preparing (I) are claimed including reducing a cpd. of (I) which bears 11-oxo gp.

USE/ADVANTAGE - (I) is antiinflammatory steroids. @(26pp)@

Derwent Class: B01;

Int Pat Class: A61K-000/00; C07C-000/00; C07J-031/00; A61K-031/56; C07J-003/00; C07J-000/00; C07J-001/00; C07J-071/00; C07J-041/00; C07J-043/00

Derwent Registry Numbers: 0361-S; 0442-S; 1685-S; 1722-S

?

?

?

?

s pn=gb2140800

S2 . . 1 PN=GB2140800
?t2/7

2/7/1 (Item 1 from file: 351)
004119333 WPI Acc No: 84-264874/43
XRAM Acc No: C84-112012
New 1-phenyl-2-amino-1-ethanol derivs. useful as beta-2 adrenergic stimulants
Patent Assignee: (GLAX) GLAXO GROUP LTD
Author (inventor): SKIDMORE I F; LUNTS L H C; FINCH H; NAYLOR A
Number of Patents: 030
Patent Family:

CC	Number	Kind	Date	Week	
DE	3414752	A	841018	8443	(Basic)
BE	899448	A	841018	8444	
SE	8402188	A	841019	8449	
GB	2140800	A	841205	8449	
AU	8427064	A	841025	8450	
NL	8401258	A	841116	8450	
FR	2545482	A	841109	8451	
JP	59199659	A	841112	8451	
NO	8401568	A	841112	8501	
DK	8402017	A	841019	8504	
HU	T33767	A	841228	8507	
FI	8401548	A	841019	8508	
ZA	8402875	A	850118	8515	
PT	78443	A	850509	8526	
LU	85329	A	850604	8541	
ES	8505641	A	851001	8603	
GB	2176476	A	861231	8652	
ES	8609209	A	861216	8707	
CH	661497	A	870731	8733	
GB	2140800	B	870923	8738	
GB	2176476	B	871231	8801	
IL	71569	A	871030	8805	
CH	667084	A	880915	8842	
JP	63264443	A	881101	8849	
DE	3448338	A	890720	8930	
AT	8401291	A	891115	8950	
SE	462594	B	900723	9032	
JP	91000858	B	910109	9105	
US	4992474	A	910212	9109	
IT	1199112	B	881230	9116	

Priority Data (CC,No,Date): GB 841889 (840125); GB 8310477 (830418); GB 8317087 (830623); GB 8329568 (831104); GB 8410124 (840418); LU 85329 (840418); GB 8612357 (860000);
Applications (CC,No,Date): DE 3414752 (840418); BE 899448 (840418); GB 8470124 (840418); NL 841258 (840418); FR 846115 (840418); JP 8478275 (840418); ZA 842875 (840417); GB 8412357 (840418); ES 539625 (850116); GB 8612357 (860521); JP 8443277 (840418); DE 3448338 (840418); US 397664 (890823);
Filing Details: DE3414752 (+23.6.83, 4.11.83-GB-017087, 029568) (367RH); BE0899448 (+23.6.83, 4.11.83-GB-017087, 029568) (367JP); GB2140800 (+23.6.83, 4.11.83-GB-017087, 029568) (367RH); NL8401258 (+23.6.83, 4.11.83-GB-017087, 029568) (367NS); FR2545482 +23.06.83, 4.11.83 (367BZ); GB2176476 (+ 23.06.83, 04.11.84-GB-017087 029568) (367SC); GB2140800 (+23.06.83; 04.11.83-GB-017087; 029568); GB2176476 derived from 18.04.84-010124; DE3448338 Div.ex 3414752 (+23.6.83, 04.11.83-GB-017087, 029568); JP91000858 (+23.6.83,4.11.83 -GB- 017087, 029568) (367MW); US4992474 (1665SV) (+19.11.86-US-932359; 23.6.83, 4.11.83-GB-317087, 329568)

of formula (I) and their salts and solvates are new. In(I) m = 2-8 and n = 1-7, provided that m+n = 4-12; Ar = phenyl opt. substd. by 1 or 2 of halogen, 1-3C alkyl and 1-3C alkoxy or by O(CH2)pO, where p = 1 or 2; R1 and R2 = H or 1-3C alkyl, provided that the total no. of C atoms in R1 and R2 is not more than 4.

USE - (I) are beta-2 adrenergic stimulants useful for treating asthma, chronic bronchitis, premature labour, depression, congestive heart disease, inflammatory and allergic skin disorders, psoriasis, glaucoma and peptic ulcers. @(82pp Dwg.No.0/0)@

Abstract (US): 9109 US 4992474

4-Hydroxy-alpha -(((6-(4-phenylbutoxy)(and corresp. propoxy cpd.) hexyl)amino) methyl)-1,3-benzenedimethanol and its 1-hydroxy-2-naphthalene carboxylate, salts and solvates, are new.

It may be prepd. e.g. by alkylation of corresp. amine.

USE - Selective stimulation of beta2-adrenoreceptors in treatment of asthma, bronchitis, etc. @(24pp)@

Abstract (GB): 8801 GB 2176476

Compounds of the general formula (II): wherein m is an integer from 2 to 8 and n is an integer from 1 to 7 with the proviso that the sum total of m+n is 4 to 12; Ar represents a phenyl group which may be unsubstituted or substituted by one or two substituents selected from halogen atoms, E1-3 alkyl and C1-3 alkoxy groups, or by an alkylenedioxy group of formula -O(CH2)pO- where p is 1 or 2; R1 and R2, which may be the same or different, each represents a hydrogen atom or a C1-3 alkyl group with the proviso that the sum total of carbon atoms in R1 and R2 is not more than 4; and Y1 is a hydrogen atom or a group convertible thereto by catalytic hydrogenation; and acid addition salts thereof. 8738 GB 2140800

Compounds of the general formula (I): wherein m is an integer from 2 to 8 and n is an integer from 1 to 7 with the proviso that the sum total of m+n is 4 to 12; Ar represents a phenyl group which may be unsubstituted or substituted by one or two substituents selected from halogen atoms, C1-3 alkyl and C1-3 alkoxy groups, or by an alkylenedioxy group of formula -O(CH2)pO- where p is 1 or 2; and R1 and R2, which may be the same or different, each represents a hydrogen atom or a C1-3 alkyl group with the proviso that the sum total of carbon atoms in R1 and R2 is not more than 4; and physiologically acceptable salts and solvates thereof.

Derwent Class: B05;

Int Pat Class: A61K-031/13; C07C-093/08; C07D-317/54; C07D-319/18; A61K-000/00; C07C-000/00; C07C-033/20; C07C-043/02; C07C-047/27; C07C-049/25; C07C-059/58; C07C-097/10; C07C-103/30; C07D-031/92; C07D-325/00; C07C-039/11; C07C-087/00; C07C-091/30; C07C-125/06; C07C-143/68; C07C-039/12; C07C-023/00; A01K-031/13; C07D-307/48; C07C-087/28; C07C-217/10; C07C-213/02; C07C-215/00

Derwent Registry Numbers: 0199-S; 0329-S; 0882-S; 1067-S; 1069-S; 1714-S

?ds

Set	Items	Description
S1	1	PN=GB2088877
S2	1	PN=GB2140800

?